Showing 731-740 of 1317 results for "".
New in My Practice: Rx/New Products
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-rxnew-products/23522/Therapeutic Review: A Host of New Treatments Emerged in 2018
https://practicaldermatology.com/topics/psoriasis/therapeutic-review-a-host-of-new-treatments-emerged-in-2018/20381/Here's a handy reference to new drugs and devices—and other key developments—this year.Physician Spotlight: Eric Schweiger, MD
Founder & CEO of Schweiger Dermatology Grouphttps://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-eric-schweiger-mdbrfounder-amp-ceo-of-schweiger-dermatology-group/23784/Prurigo Nodularis: An Update for Clinicians, Part 1
https://practicaldermatology.com/topics/general-topics/prurigo-nodularis-an-update-for-clinicians-part-1/20507/Here's a look at the diagnosis of an “eczematous” condition with an unclear etiology.Resolution of Primary Erythromelalgia Following Ibuprofen; Fire Power
https://practicaldermatology.com/youngmd-connect/resident-resource-center/resolution-of-primary-erythromelalgia-following-ibuprofen-fire-power/20619/GLP-1 Receptor Agonists: Current Roles in Medicine
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-current-roles-in-medicine/48897/In recent years, the popularity of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has skyrocketed, along with interest in clinical applications beyond diabetes and weight management. Here, we present a brief review of GLP-1RAs, including a history, a look at the mechanism of action, pivotal rePRP: What Dermatologists Should Know
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/prp-what-dermatologists-should-know/20333/Long used in orthopedic medicine and made popular on social media, PRP has science to support its use in dermatology.Driving Practice Value: The Competitive Sale Process
https://practicaldermatology.com/topics/practice-management/driving-practice-value-the-competitive-sale-process/24007/AbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anPsychodermatology: A Review
https://practicaldermatology.com/topics/practice-management/psychodermatology-a-review/21180/